CMS Targets Prior Authorization Delays in Medicare Advantage Drug Coverage

If you've ever been told by your Medicare Advantage plan that your doctor needs to get prior authorization before you can fill a prescription, you already know how frustrating — and sometimes frightening — that process can be. You're waiting at the pharmacy counter, or you're at home in pain, while an insurance company decides whether your doctor's clinical judgment meets their internal standards. A proposed rule from the Centers for Medicare and Medicaid Services takes direct aim at that problem, and if it becomes final, it could meaningfully change how Medicare Advantage plans handle drug coverage decisions for tens of millions of older Americans.

Prior authorization, commonly called PA, requires your Medicare Advantage plan to approve a specific drug before it will cover the cost. In theory, it ensures that expensive or potentially risky medications are being used appropriately. In practice, it has become one of the most complained-about features of Medicare Advantage coverage. Doctors spend hours on paperwork. Seniors wait days — sometimes more than a week — for decisions. And denials, even when later overturned on appeal, can cause dangerous gaps in treatment for conditions like diabetes, heart disease, cancer, and serious mental illness. The proposed CMS rule is a direct response to that documented pattern of harm.

The proposal would establish binding timelines for how quickly plans must respond to prior authorization requests for prescription drugs. For standard requests, the rule calls for decisions within 72 hours. For urgent or expedited requests — situations where a delay could seriously harm a patient — the window would shrink to 24 hours. These concepts are not entirely new to Medicare policy, but applying them specifically and consistently to drug prior authorization across all Medicare Advantage plans is a significant step. Currently, plans have considerable flexibility in how they structure these timelines, and the variation from plan to plan and state to state is wide enough to be genuinely confusing for beneficiaries trying to understand their rights.

Data Snapshot: According to CMS.gov data, Medicare Advantage enrollment reached approximately 33.8 million beneficiaries in 2024, representing more than half of all Medicare enrollees nationwide. CMS has also reported that in 2021 alone, Medicare Advantage plans issued approximately 35 million prior authorization determinations for medical services and drugs combined. A 2022 report from the HHS Office of Inspector General found that 13 percent of prior authorization denials that were later appealed and overturned met Medicare coverage rules all along — meaning those initial denials were not clinically justified under the program's own standards. The proposed rule is, in substantial part, a regulatory response to that finding.

One of the most consequential elements of the proposal is a new transparency requirement. CMS is proposing that Medicare Advantage plans publicly report their prior authorization data in a standardized format — including approval rates, denial rates, and the rate at which denials are overturned on appeal, broken down by drug type. This matters enormously during the Annual Enrollment Period, which runs October 15 through December 7 each year. Right now, you can compare plans on monthly premiums, star ratings, and formulary tiers. Under this proposal, you could also compare plans on how often they say no to your doctor's prescription requests — and how often those no's get reversed. That is a genuinely new and useful tool for choosing coverage.

The rule also addresses what clinical criteria plans are permitted to use when making prior authorization decisions. Some plans currently apply guidelines that are years out of date, or they use criteria more restrictive than Medicare's own national and local coverage determinations. The proposal would require plans to base prior authorization decisions on current, evidence-based clinical standards and to ensure those standards are consistent with what Medicare itself has determined is medically appropriate. In plain terms: if Medicare's own coverage rules say a drug is appropriate for your condition, your plan could not deny it based on an internal guideline written five years ago that hasn't been updated to reflect current medical evidence.

For beneficiaries who receive a denial, the proposed rule would also strengthen the appeals process in a practical way. Under current rules, you have the right to appeal, but denial notices are often vague — they may cite a plan policy number without explaining in understandable language why your specific drug was rejected. The proposal would require denial notices to explain in plain language exactly why the drug was denied and which clinical criteria were applied. This matters because a vague denial letter makes it far harder for you or your doctor to build a successful appeal. Knowing the precise reason for a denial is the essential first step toward overturning it, and right now that information is frequently buried or absent entirely.

Under current Medicare law, you already have meaningful appeal rights that many beneficiaries don't know about. If your Medicare Advantage plan denies a prior authorization request, you can file a standard appeal and the plan must respond within 30 days. If your situation is urgent — meaning a delay would seriously harm your health — you can request an expedited appeal and the plan must respond within 72 hours. If the plan upholds the denial, you can escalate to an Independent Review Organization, then to an Administrative Law Judge, and ultimately to federal court. Research consistently shows that a large share of denials that are appealed are ultimately reversed, which means pursuing an appeal is often worth the effort when your doctor believes the drug is medically necessary.

Prior authorization fits into a broader set of tools Medicare Advantage plans use to manage drug costs and utilization. Most Medicare Advantage plans include prescription drug coverage — these are called MA-PD plans — and each maintains a formulary, which is a tiered list of covered drugs. Prior authorization is one of three main utilization management tools, alongside step therapy (requiring you to try a cheaper drug before a more expensive one) and quantity limits. The proposed rule focuses specifically on prior authorization timelines and transparency, but it is part of a broader CMS effort to rein in coverage restrictions that beneficiaries and physicians have argued go well beyond what is clinically or legally justified under Medicare rules.

If you are currently enrolled in a Medicare Advantage plan and you take drugs that require prior authorization, there are practical steps you can take right now, regardless of when or whether this rule is finalized. Ask your doctor's office to keep copies of all prior authorization requests and responses — this paper trail is invaluable if you need to appeal. If you receive a denial, request an expedited appeal immediately if your health situation is urgent. Your State Health Insurance Assistance Program counselor can walk you through the appeals process at no cost; find your local SHIP counselor at shiphelp.org. These are free, unbiased advisors funded by the federal government specifically to help Medicare beneficiaries navigate situations like this.

During the Annual Enrollment Period — October 15 through December 7 — you can switch Medicare Advantage plans if your current plan's prior authorization practices are creating problems for your care. If you miss that window, the Medicare Advantage Open Enrollment Period runs January 1 through March 31 and allows you to switch from one Medicare Advantage plan to another, or to return to Original Medicare. If you return to Original Medicare, you can add a standalone Part D drug plan and consider a Medigap supplemental policy. Be aware that in most states, Medigap plans require medical underwriting outside of guaranteed issue periods, which can affect your eligibility or premium. Thirteen states — including California, New York, and Oregon — have birthday rules or other protections that give you a window to switch Medigap plans without underwriting; check with your state insurance department to see whether those protections apply to you.

The proposed rule is not yet final. The federal rulemaking process includes a public comment period during which insurance companies, patient advocates, physicians, and individual beneficiaries can submit feedback to CMS. Proposed rules of this nature typically go through significant revision before they are finalized, and the insurance industry has consistently opposed prior authorization reforms, arguing that these requirements help control costs and prevent inappropriate prescribing. Patient advocacy organizations and physician groups have countered that the current system causes measurable harm — delayed treatments, worsened health outcomes, and an administrative burden that falls disproportionately on older and sicker patients.

You can submit a public comment during the comment period at federalregister.gov, and your personal experience with prior authorization delays is exactly the kind of real-world evidence that CMS says it considers during rulemaking. Organizations including AARP and the Medicare Rights Center track these regulatory changes and publish plain-language summaries that can help you stay informed without reading hundreds of pages of federal rulemaking text. The Medicare Rights Center's helpline at 800-333-4114 is another free resource if you need help understanding a denial or navigating an appeal.

The bottom line for Medicare Advantage enrollees is straightforward: prior authorization for prescription drugs is a real and present obstacle for many seniors, and CMS is proposing meaningful reforms to make the process faster, more transparent, and more accountable to clinical evidence. Whether you are managing a chronic condition that requires ongoing medications or you have recently been prescribed a new drug your plan is questioning, understanding your rights under both current law and proposed changes is essential. The best defense against a prior authorization delay is knowing the process, knowing your appeal rights, having a doctor's office willing to advocate for you — and a regulatory environment that requires plans to justify their decisions clearly, quickly, and in language you can actually understand.